nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.0695	0.0695	CbGpPWpGaD
Aclidinium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.069	0.069	CbGpPWpGaD
Aclidinium—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0317	0.0317	CbGpPWpGaD
Aclidinium—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0304	0.0304	CbGpPWpGaD
Aclidinium—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0267	0.0267	CbGpPWpGaD
Aclidinium—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.0255	0.0255	CbGpPWpGaD
Aclidinium—BCHE—Peptide hormone metabolism—CGA—conduct disorder	0.0232	0.0232	CbGpPWpGaD
Aclidinium—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0214	0.0214	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0213	0.0213	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0211	0.0211	CbGpPWpGaD
Aclidinium—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0207	0.0207	CbGpPWpGaD
Aclidinium—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0198	0.0198	CbGpPWpGaD
Aclidinium—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.018	0.018	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0179	0.0179	CbGpPWpGaD
Aclidinium—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0178	0.0178	CbGpPWpGaD
Aclidinium—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0174	0.0174	CbGpPWpGaD
Aclidinium—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0167	0.0167	CbGpPWpGaD
Aclidinium—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.014	0.014	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0139	0.0139	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0138	0.0138	CbGpPWpGaD
Aclidinium—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0136	0.0136	CbGpPWpGaD
Aclidinium—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.013	0.013	CbGpPWpGaD
Aclidinium—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0117	0.0117	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0117	0.0117	CbGpPWpGaD
Aclidinium—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Aclidinium—BCHE—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.011	0.011	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.00947	0.00947	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.00938	0.00938	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00937	0.00937	CbGpPWpGaD
Aclidinium—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00917	0.00917	CbGpPWpGaD
Aclidinium—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00914	0.00914	CbGpPWpGaD
Aclidinium—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00905	0.00905	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00897	0.00897	CbGpPWpGaD
Aclidinium—BCHE—Neuronal System—GABRA2—conduct disorder	0.00842	0.00842	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00713	0.00713	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00683	0.00683	CbGpPWpGaD
Aclidinium—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.0066	0.0066	CbGpPWpGaD
Aclidinium—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00648	0.00648	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00632	0.00632	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0063	0.0063	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00623	0.00623	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00618	0.00618	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00612	0.00612	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00612	0.00612	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00586	0.00586	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00536	0.00536	CbGpPWpGaD
Aclidinium—BCHE—Transmission across Chemical Synapses—COMT—conduct disorder	0.00529	0.00529	CbGpPWpGaD
Aclidinium—BCHE—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00525	0.00525	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00525	0.00525	CbGpPWpGaD
Aclidinium—BCHE—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00508	0.00508	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00504	0.00504	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00502	0.00502	CbGpPWpGaD
Aclidinium—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.00495	0.00495	CbGpPWpGaD
Aclidinium—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00488	0.00488	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00481	0.00481	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00479	0.00479	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00475	0.00475	CbGpPWpGaD
Aclidinium—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00443	0.00443	CbGpPWpGaD
Aclidinium—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00439	0.00439	CbGpPWpGaD
Aclidinium—BCHE—Metabolism of proteins—CGA—conduct disorder	0.00439	0.00439	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00413	0.00413	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00412	0.00412	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Aclidinium—BCHE—Neuronal System—COMT—conduct disorder	0.00405	0.00405	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.00403	0.00403	CbGpPWpGaD
Aclidinium—BCHE—Neuronal System—MAOA—conduct disorder	0.00402	0.00402	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00399	0.00399	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00399	0.00399	CbGpPWpGaD
Aclidinium—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00398	0.00398	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00386	0.00386	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00366	0.00366	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00354	0.00354	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00353	0.00353	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00351	0.00351	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00349	0.00349	CbGpPWpGaD
Aclidinium—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00348	0.00348	CbGpPWpGaD
Aclidinium—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00347	0.00347	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00342	0.00342	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00328	0.00328	CbGpPWpGaD
Aclidinium—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00312	0.00312	CbGpPWpGaD
Aclidinium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00311	0.00311	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00272	0.00272	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00271	0.00271	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00266	0.00266	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00266	0.00266	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.00261	0.00261	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.0025	0.0025	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00247	0.00247	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00246	0.00246	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00244	0.00244	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00231	0.00231	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0023	0.0023	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00228	0.00228	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—CGA—conduct disorder	0.00226	0.00226	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.00226	0.00226	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Aclidinium—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00211	0.00211	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00207	0.00207	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00205	0.00205	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00196	0.00196	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00176	0.00176	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00174	0.00174	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—CGA—conduct disorder	0.00174	0.00174	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.00166	0.00166	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.0015	0.0015	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00147	0.00147	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00146	0.00146	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00144	0.00144	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.00141	0.00141	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00136	0.00136	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.00134	0.00134	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00128	0.00128	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.00121	0.00121	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00116	0.00116	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.00116	0.00116	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.00115	0.00115	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—COMT—conduct disorder	0.00102	0.00102	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—MAOA—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000993	0.000993	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.00099	0.00099	CbGpPWpGaD
Aclidinium—BCHE—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000983	0.000983	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.00098	0.00098	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.000902	0.000902	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.000899	0.000899	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.00089	0.00089	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000817	0.000817	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000814	0.000814	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000806	0.000806	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.00079	0.00079	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—COMT—conduct disorder	0.000785	0.000785	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—MAOA—conduct disorder	0.000779	0.000779	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.000757	0.000757	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000533	0.000533	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000531	0.000531	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000526	0.000526	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—EP300—conduct disorder	0.000438	0.000438	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000419	0.000419	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EP300—conduct disorder	0.000401	0.000401	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—EP300—conduct disorder	0.000336	0.000336	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EP300—conduct disorder	0.000282	0.000282	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000281	0.000281	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000279	0.000279	CbGpPWpGaD
